EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria

Getnet M Assefa, Jason A Roberts, Abdullah T Aslan, Solomon A Mohammed, Fekade B Sime iD

Journal of Antimicrobial Chemotherapy · 03.02.2025 · 80 (2) · 334-346

DOI: 10.1093/jac/dkae451 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 17.12.2024. Verfasst von Getnet M Assefa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Azabicyclo Compounds, Carbapenems, Ceftazidime. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Carbapenem-resistant Gram-negative bacteria (CR-GNB) develop resistance to many antimicrobials. To effectively manage infections caused by these organisms, novel agents and/or combinations of antimicrobials are required.

Objectives

Evaluated the in vitro efficacy of ceftazidime/avibactam in combination with other antimicrobials against CR-GNB.

Methods

PubMed, Web of Science, Embase and Scopus were searched. Study outcomes were quantified by counting the number of isolates exhibiting synergy, defined as a fractional inhibitory concentration index ≤ 0.5 for checkerboard and Etest, and a >2 log cfu/mL reduction for time-kill studies. The proportion of synergy was calculated as the ratio of isolates exhibiting synergy to the total number of isolates tested. These proportions were analysed using a random-effects model, following the Freeman–Tukey double-arcsine transformation.

Results

Forty-five in vitro studies were included. A total of 734 isolates were tested, and 69.3% of them were resistant to ceftazidime/avibactam. The combination of ceftazidime/avibactam with aztreonam showed a high synergy rate against carbapenem-resistant Klebsiella pneumoniae (effect size, ES = 0.91–0.98) and Escherichia coli (ES = 0.75–1.00). Ceftazidime/avibactam also demonstrated a high synergy rate (ES = 1) in time-kill studies when combined with azithromycin, fosfomycin and gentamicin against K. pneumoniae. Compared to ceftazidime/avibactam alone, a higher bactericidal rate was reported when ceftazidime/avibactam was combined with other antimicrobials against carbapenem-resistant K. pneumoniae (57% versus 31%) and E. coli (93% versus 0%).

Conclusions

Ceftazidime/avibactam frequently demonstrates synergistic bactericidal activity when combined with various antimicrobials against CR-GNB in in vitro tests. Further pre-clinical and clinical studies are warranted to validate the utility of ceftazidime/avibactam-based combination regimens for CR-GNB infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsAzabicyclo CompoundsCarbapenemsCeftazidimeGram-Negative Bacterial InfectionsHumansDrug CombinationsDrug Resistance, Multiple, BacterialDrug SynergismGram-Negative BacteriaMicrobial Sensitivity Tests

Substanzen

Anti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsCarbapenemsCeftazidimeDrug Combinations

Autor:innen und Institutionen

  • Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
  • Department of Pharmacy, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia.
  • Pharmacy Department, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
  • Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
  • Herston Infectious Disease Institute (HeIDI), Metro North Health, Brisbane, QLD, Australia.
  • Division of Anaesthesiology Critical Care Emerging and Pain Medicine, Nimes University Hospital, University of Montpellier, Nimes, France.

ORCID-Profile: Fekade B Sime

Zitieren

APA

Assefa, G. M., Roberts, J. A., Aslan, A. T., Mohammed, S. A., & Sime, F. B. (2025). A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria. Journal of Antimicrobial Chemotherapy, 80(2), 334-346. https://doi.org/10.1093/jac/dkae451

Vancouver

Assefa GM, Roberts JA, Aslan AT, Mohammed SA, Sime FB. A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria. Journal of Antimicrobial Chemotherapy. 2025;80(2):334-346. doi:10.1093/jac/dkae451

BibTeX
@article{Assefa2025,
  author = {Assefa, Getnet M and Roberts, Jason A and Aslan, Abdullah T and Mohammed, Solomon A and Sime, Fekade B},
  title = {A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {2},
  pages = {334--346},
  doi = {10.1093/jac/dkae451}
}
Kostenlos starten →